Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor

Cancer Research

Volumn 73, Issue 13, 2013, Pages 3963-3973

  Keshava, Shiva ^a   Sahoo, Sanghamitra ^a   Tucker, Torry A ^a   Idell, Steven ^a   Rao, L Vijaya Mohan ^a   Pendurthi, Usha R ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL PROTEIN C RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; NUDE MOUSE; PLEURA CAVITY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPOPROTEINS; MESOTHELIOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLEURAL NEOPLASMS; RECEPTOR, PAR-1; RECEPTOR, PAR-2; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; THROMBOMODULIN; THROMBOPLASTIN; TUMOR BURDEN;

EID: 84880050914     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1690     Document Type: Article

References (54)

1. Trousseau A. Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris. N Sydenham Soc 1865;3: 654-712.
2. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977;56: 1-37.
3. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: trousseau's syndrome revisited. Blood 1983;62: 14-31.
4. Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 2008; 34: 154-60.
5. Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996;3: 379-84.
6. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10: 355-62.
7. Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis. Thromb Res 2010;125 Suppl 2: S36-S38.
8. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009;27: 4834-8.
9. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012;119: 924-32.
10. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006;32 Suppl 1: 61-8.
11. Fischer EG, Ruf W, Mueller BM. Tissue factor-initiated thrombin generation activates the signalling thrombin receptor on malignant melanoma cells. Cancer Res 1995;55: 1629-32.
12. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007;110: 133-41.
13. Camerer E. Protease signaling in tumor progression. Thromb Res 2007;120 Suppl 2: S75-S81.
14. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Feldinghabermann B, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008;111: 190-9.
15. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105: 1734-41.
16. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk G, Rote WE, Green SJ, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63: 2997-3000.
17. Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007;33: 643-52.
18. Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 2008;68: 7219-27.
19. Williams L, Tucker TA, Koenig K, Allen T, Rao LV, Pendurthi U, et al. Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice. Am J Respir Cell Mol Biol 2012;46: 173-9.
20. Ghosh S, Pendurthi UR, Steinoe A, Esmon CT, Rao LV. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007;282: 11849-57.
21. Preston RJ, Ajzner E, Razzari C, Karageorgi S, Dua S, Dahlback B, et al. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem 2006;281: 28850-7.
22. Lopez-Sagaseta J, Montes R, Puy C, Diez N, Fukudome K, Hermida J. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J Thromb Haemost 2007;5: 1817-24.
23. Sen P, Gopalakrishan R, Kothari H, Keshava S, Clark C, Esmon CT, et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood 2011;117: 3199-208.
24. Disse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon CT, et al. The endothelial protein c receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem 2011;286: 5756-67.
25. Beaulieu LM, Church FC. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res 2007;313: 677-87.
26. Gramling MW, Beaulieu LM, Church FC. Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Exp Cell Res 2010;316: 314-28.
27. Van Sluis GL, Niers TM, Esmon CT, Tigchelaar W, Richel DJ, Buller HR, et al. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 2009;114: 1968-73.
28. Bezuhly M, Cullen R, Esmon CT, Morris SF, West KA, Johnston B, et al. Role of activated protein C and its receptor in inhibition of tumor metastasis. Blood 2009;113: 3371-4.
29. Anton I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazabal C, et al. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 2012;186: 96-105.
30. Tucker TA, Dean C, Komissarov AA, Koenig K, Mazar AP, Pendurthi U, et al. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells. Am J Respir Cell Mol Biol 2010;42: 685-96.
31. Pendurthi UR, Williams JT, Rao LVM. Acidic and basic fibroblast growth factors suppress transcriptional activation of tissue factor and other inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol 1997;17: 940-6.
32. Mandal SK, Pendurthi UR, Rao LV. Tissue factor trafficking in fibroblasts: involvement of protease-activated receptor-mediated cell signaling. Blood 2007;110: 161-70.
33. HorowitzNA, Blevins EA, MillerWM,Perry AR, Talmage KE, Mullins ES, et al. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood 2011;118: 2889-95.
34. Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, et al. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 1998;101: 1301-9.
35. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92: 8205-9.
36. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998;101: 1372-8.
37. Tsuneyoshi N, Fukudome K, Horiguchi S, Ye X, Matsuzaki M, Toi M, et al. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost 2001;85: 356-61.
38. Menschikowski M, Hagelgans A, Tiebel O, Klinsmann L, Eisenhofer G, Siegert G. Expression and shedding of endothelial proteinCreceptor in prostate cancer cells. Cancer Cell Int 2011;11: 4.
39. Scheffer GL, Flens MJ, Hageman S, Izquierdo MA, Shoemaker RH, Scheper RJ. Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer 2002;38: 1535-42.
40. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007;13: 1349-58.
41. Joyce DE, Gelbert L, Ciaccia A, Dehoff B, GrinnellBW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276: 11199-203.
42. Cheng T, Liu D, Griffin J, Fernandez J, Castellino F, Rosen E, et al. Activated proteinCblocks p53 mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9: 338-42.
43. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernandez JA, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004;41: 563-72.
44. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003;373: 65-70.
45. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109: 3161-72.
46. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeabilityenhancing to a barrier-protective response in endothelial cells. Blood 2007;110: 3909-16.
47. Bae JS, Rezaie AR. Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thromb Haemost 2009;101: 513-20.
48. Gleeson EM, O'Donnell JS, Preston RJ. The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. Cell Mol Life Sci 2012;69: 717-26.
49. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 2002;30: S288-S293.
50. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140: 883-99.
51. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9: 798-809.
52. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454: 436-44.
53. van der Most RG, Robinson BW, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years. Cancer Gene Ther 2006; 13: 897-904.
54. Vachani A, Sterman DH, Albelda SM. Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol 2007;2: 265-7.